Clinical trial
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic…
NCT00352001 · Mikkael Sekeres MD, Other · Completed
Key facts
| NCT number | NCT00352001 |
|---|---|
| Title | Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes |
| Official title | A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Mikkael Sekeres MD, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | azacitidine, lenalidomide |
| Enrollment | 37 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2011 |
| Completion | Sep 1, 2011 |
| First posted | Jul 14, 2006 |
| Last update posted | Sep 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: